Trial Profile
A 52-week Randomized, Double-blind, Double-dummy, Active and Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin Compared to Glimepiride or Placebo Added to Metformin in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control With Metformin Monotherapy
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 24 Dec 2021
Price :
$35
*
At a glance
- Drugs Sotagliflozin (Primary) ; Glimepiride; Metformin
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms SOTA-GLIM
- Sponsors Lexicon Pharmaceuticals; Sanofi
- 21 Jul 2020 Primary endpoint (Change in hemoglobin A1c (for sotagliflozin dose1)) has been met, according to a Lexicon Pharmaceuticals Media Release
- 21 Jul 2020 According to a Lexicon Pharmaceuticals Media Release, final results from this study will be preserved for upcoming medical congresses and publications.
- 21 Jul 2020 Results presented in the Lexicon Pharmaceuticals Media Release.